News | November 01, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Subscribe To Our Newsletter & Stay Updated
